Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Biotech
Inflammation biotech Evommune eyes IPO to fund dermatitis trials
Evommune has become the latest indicator that drug developers are once again tempted by the public markets.
James Waldron
Oct 10, 2025 6:35am
Jasper halves workforce after dud drug surprise, narrows R&D focus
Jul 9, 2025 9:07am
Jasper warns of restructuring after dud drug derails trials
Jul 7, 2025 9:23am
Third Harmonic’s song to end as biotech looks to liquidate
Apr 14, 2025 9:01am
Novartis hands over $55M to license preclinical hives prospect
Mar 3, 2025 5:05pm
Third Harmonic halves headcount to take urticaria drug to ph. 2
Feb 11, 2025 7:58am
